MONROVIA (AFP): The first large-scale trials of two Ebola vaccines were due to begin in Liberia on Monday, the partnership conducting the research said. The vaccines contain harmless fragments of the virus that trigger an immune response, according to the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL), a collaboration between the United States and Liberia. ‘The study will begin at Redemption Hospital in Monrovia. Subsequent sites will be added at other hospitals in and near Monrovia after the first 600 participants join the study,’ it said in a statement.